The condition is typically treated using drugs delivered via eye drops to help decrease ... represents a potentially exciting new alternative to existing glaucoma treatments.

Legislation under consideration in Trenton could modernize the scope of access to modern eye care in New Jersey.

Glaucoma is the leading cause of blindness worldwide. Its symptoms do not present themselves in an obvious way, which has led to the condition being dubbed the ‘silent thief of sight’.

Health care and tech innovation go hand in hand. From delivering steady streams of medication to speeding up treatment of ...

Primary Open-angle, Closed-angle, Normal-tension, and Congenital are common types of glaucoma. Eye drops serve as the primary ...

Although the idea of eye drops changing eye colour may seem far-fetched, an expert claims it's not entirely impossible. Certain glaucoma treatments, for instance, can cause eye pigmentation to ...

The global glaucoma treatment market is projected to grow from USD 5.7 billion in 2022 to USD 8.0 billion by 2033, at a CAGR ...

The goal is to address a common problem among glaucoma patients. “I don’t always get the drops in the eye, and then after a while, I just forgot about them and whatnot. So that’s part of ...

Background Normal tension glaucoma ... right eye was used for statistical analysis. Results In 41 right eyes, the mean pre-study IOP was 14.3 ± 3.4 mmHg while on 1.5 ± 0.8 eye drops.

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced a research partnership with the John A.